Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions

被引:60
作者
Balakumar, Pitchai [1 ]
Arora, Mandeep Kumar [1 ]
Ganti, Subrahmanya S. [1 ]
Reddy, Jayarami [1 ]
Singh, Manjeet [1 ]
机构
[1] ISF Coll Pharm, Cardiovasc Pharmacol Div, Moga 142001, Punjab, India
关键词
Diabetes; Diabetic nephropathy; Target sites; Pharmacological interventions; PROTEIN-KINASE-C; GROWTH-FACTOR-BETA; GLYCATION END-PRODUCTS; ANGIOTENSIN-II; TGF-BETA; GENE-EXPRESSION; NADPH OXIDASE; COMBINATION THERAPY; NITROSATIVE STRESS; RECEPTOR BLOCKER;
D O I
10.1016/j.phrs.2009.02.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic diabetes mellitus is associated with various complications such as retinopathy, neuropathy, nephropathy, cardiomyopathy, vasculopathy, dermatopathy and encephalopathy. Nephropathy is one of the major complications of diabetes mellitus, and the morbidity and mortality due to diabetic nephropathy is constantly progressing in industrialized nations. No satisfactory therapeutic option is Currently available to treat patients with nephropathy except for fewer agents like angiotensin converting enzyme inhibitors, angiotensin AT(1) receptor blockers and few antioxidants, which have been shown to improve the function of diabetic kidney to some extent. Thus, tremendous efforts are being made to explore promising therapeutic interventions to treat diabetic nephropathy. This review discussed various presently employed and recently developed pharmacological interventions to treat diabetic nephropathy and to improve the function of diabetic kidney. In addition, the recently identified potential target sites involved in the pathogenesis of diabetic nephropathy have been delineated. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:24 / 32
页数:9
相关论文
共 135 条
  • [1] Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression
    Akahori, H
    Ota, T
    Torita, M
    Ando, H
    Kaneko, S
    Takamura, T
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (02) : 514 - 521
  • [2] ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1
    Amann, B
    Tinzmann, R
    Angelkort, B
    [J]. DIABETES CARE, 2003, 26 (08) : 2421 - 2425
  • [3] RENAL RENIN-ANGIOTENSIN SYSTEM IN DIABETES - FUNCTIONAL, IMMUNOHISTOCHEMICAL, AND MOLECULAR BIOLOGICAL CORRELATIONS
    ANDERSON, S
    JUNG, FF
    INGELFINGER, JR
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (04): : F477 - F486
  • [4] Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats
    Anjaneyulu, M
    Chopra, K
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (04): : 244 - 248
  • [5] [Anonymous], 2008, Clin. Nutr. ESPEN
  • [6] Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics
    Baba, S
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2001, 54 (03) : 191 - 201
  • [7] RENAL EFFECTS OF NICARDIPINE, A CALCIUM-ANTAGONIST, IN HYPERTENSIVE TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS WITH AND WITHOUT NEPHROPATHY
    BABA, T
    TOMIYAMA, T
    MURABAYASHI, S
    TAKEBE, K
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (05) : 425 - 429
  • [8] BAKRIS CL, 1994, KIDNEY INT, V54, P1283
  • [9] Experimental models for nephropathy
    Balakumar, Pitchai
    Chakkarwar, Vishal Arvind
    Kumar, Vijay
    Jain, Akash
    Reddy, Jayarami
    Singh, Majeet
    [J]. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2008, 9 (04) : 189 - 195
  • [10] Emerging role of PPAR ligands in the management of diabetic nephropathy
    Balakumar, Pitchai
    Arora, Mandeep Kumar
    Singh, Manjeet
    [J]. PHARMACOLOGICAL RESEARCH, 2009, 60 (03) : 170 - 173